Evidence map›Paper›PMID 28748356›Full record

ArticleInternational journal of clinical oncology2017

PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.

Xiaohui Zhang, Yuanyuan Zeng, Qiuxia Qu, Jianjie Zhu, Zeyi Liu, Weiwei Ning, Hui Zeng, Nan Zhang, Wenwen Du, Cheng Chen and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 197 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
197citing papers in PubMed, 3 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

197 citing papers in PubMed, 3 syntheses or guidelines pooled it, 306 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

137 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Xiaohui ZhangDepartment of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, People's Republic of China.
Yuanyuan ZengDepartment of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, People's Republic of China.
Qiuxia QuThe Biotechnology Research Institute of Soochow University, Suzhou, People's Republic of China.
Jianjie ZhuDepartment of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, People's Republic of China.
Zeyi LiuDepartment of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, People's Republic of China.
Weiwei NingDepartment of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, People's Republic of China.
Hui ZengDepartment of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, People's Republic of China.
Nan ZhangDepartment of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, People's Republic of China.
Wenwen DuDepartment of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, People's Republic of China.
Cheng ChenDepartment of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, People's Republic of China. chenchengatsd@sohu.com.
Jian-An HuangDepartment of Respiratory Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215123, People's Republic of China. huang_jian_an@163.com.
Soochow University · CNFirst Affiliated Hospital of Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterferon-γ (IFN-γ) is conventionally regarded as an inflammatory cytokine that has a pivotal role in anti-infection and tumor immune surveillance. It has been used clinically to treat a variety of malignancies. However, increased evidence has suggested IFN-γ can act to induce tumor progression. The role of IFN-γ in regulating antitumor immunity appears to be complex and paradoxical. The mechanism underlying the dual aspects of IFN-γ function in antitumor immunity is not clear.

methods(1) Lung cancer cells (A549 cells) were cultured with pleural effusion or supernatant of tumor-associated macrophages (TAMs supernatant), and the expression levels of PD-L1 were detected by flow cytometer. The invasion capacity was measured in vitro using trans-well migration assays. (2) Pleural effusion mononuclear cells (PEMC) were separated by Ficoll Hypaque gradient. The expression of interleukin (IL)-6, IL-10, tumor necrosis factor (TNF)-α, and INF-γ in the tumor-associated macrophages was analyzed by flow cytometry. (3) A549 cells were stimulated with IL-6, IL-10, TNF-α, or IFN-γ and then the expression levels were detected by flow cytometry. (4) The expression levels of phospho-ERK (p-ERK), phospho-AKT (p-AKT), and phospho-Sat3 (p-Stat3) were analyzed with Western blot after stimulation with IFN-γ. (5) Cotreatment of the A549 cells with MAPK/ERK-specific inhibitor PD98059, PI3K/AKT-specific inhibitor LY294002, or JAK/STAT3-specific inhibitor AG490, respectively, blocked IFN-γ-induced PD-L1 expression, and then PD-L1 expression was detected by flow cytometry.

resultsWe demonstrated that TAMs could induce the expression of PD-L1 by the secretion of IFN-γ through the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling pathway and the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway in A549 cells. Furthermore, the signal pathway blockers LY294002 or AG490 could block the induced expression of PD-L1 by IFN-γ.

conclusionsIFN-γ was not always successful as an antitumor agent. It also can promote tumor cells to evade immune surveillance. Researchers should be cautious in using IFN-γ as a therapeutic agent for cancer treatment.

Indexed as

B7-H1 AntigenCell Line, TumorFlavonoidsHumansInterferon-gammaInterleukin-10Interleukin-6Janus KinasesLung NeoplasmsMacrophagesPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktSignal TransductionSTAT3 Transcription FactorTumor Necrosis Factor-alpha2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-onealpha-cyano-(3,4-dihydroxy)-N-benzylcinnamideB7-H1 AntigenCD274 protein, humanFlavonoidsIL10 protein, humanIL6 protein, humanInterferon-gammaInterleukin-10Interleukin-6Janus KinasesPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktSTAT3 protein, humanSTAT3 Transcription FactorTumor Necrosis Factor-alphaTyrphostinsCytokineLung cancerPD-L1Signaling pathwayTumor-associated macrophageTumor microenvironment

Identifiers

PMID28748356
OpenAlexW2738879667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.